BioSpace News Archive

Award Recognizes Israeli Companies Working to Combat Coronavirus and the Damage of Future Pandemics

iTeos Therapeutics, Inc. announced that Michel Detheux, PhD, President and Chief Executive Officer, will present a company overview at the 39th Annual J.P. Morgan Conference, being held virtually on Tuesday, January 12, 2021 at 9:10 a.m. ET.

Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, today announced that a corporate update will be presented at the 39 th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 4:30pm ET. A live webcast of the event can be acce

Clinical evidence supporting the company’s platform for nerve repair will be featured in several presentations during the scientific sessions

MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference.

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET. The conference will be held in a virtual meeting format. The presentation will be given by Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, and wi

Provides Ortho RTI with worldwide rights to commercialize Buoy Suspension Fractional System in combination with Ortho-R

Marker Therapeutics, Inc. (Nasdaq:MRKR), today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the Company’s Phase 2 trial investigating the safety and efficacy of MT-401

Sierra Oncology, Inc. announced that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the H.C. Wainwright 2021 BioConnect Virtual Conference taking place January 11-14, 2021.

Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced the closing of an $88 million Series A financing.